Association between different corticosteroid regimens used in severe SARS-CoV-2 infection and short-term mortality : retrospective cohort study
Copyright © 2024 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Publicado por Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: During the SARS-CoV-2 pandemic, several corticosteroid regimens have been used in the treatment of the disease, with disparate results according to drug and regimen used. For this reason, we wanted to analyze differences in early mortality derived from the use of different regimens of dexamethasone and methylprednisolone in SARS-CoV-2 infection in critically ill patients requiring admission to an ICU.
METHOD: Observational, analytical and retrospective study, in an intensive care unit of a third-level university hospital, (March 2020 and June 2021). Adult patients (>18 years old) who were admitted consecutively for proven SARS-CoV-2 infection were included. The association with mortality in ICU at 28 days, different corticosteroid regimens used, was analyzed using a Cox proportional risk regression model.
RESULTS: Data from a cohort of 539 patients were studied. Patient age (RR: 1.06; 95% CI: 1.02-1.10; P=<0.01) showed a significant association with 28-day mortality in the ICU. In the comparison of the different corticosteroid regimens analyzed, taking as a reference those patients who did not receive corticosteroid treatment, the dose of dexamethasone of 6mg/day showed a clear trend towards statistical significance as a protector of mortality at 28 days in the ICU (RR: 0.40, 95% CI: 0.15-1.02, p=0.05). The dose of dexamethasone of 6mg/day and low doses of methylprednisolone show a similar association with survival at 28 days (OR: 1.19; 95% CI: 0.63-2.26).
CONCLUSIONS: The use of corticosteroids has been associated with better mortality outcomes in severe cases of SARS-CoV-2 infection. However, the therapeutic benefits of corticosteroids are not limited to dexamethasone alone.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Revista espanola de anestesiologia y reanimacion - (2024) vom: 21. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
González-Castro, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
28-day mortality |
|---|
| Anmerkungen: |
Date Revised 05.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.redare.2024.02.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368852830 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368852830 | ||
| 003 | DE-627 | ||
| 005 | 20240306233015.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.redare.2024.02.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM368852830 | ||
| 035 | |a (NLM)38395302 | ||
| 035 | |a (PII)S2341-1929(24)00034-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a González-Castro, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between different corticosteroid regimens used in severe SARS-CoV-2 infection and short-term mortality |b retrospective cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: During the SARS-CoV-2 pandemic, several corticosteroid regimens have been used in the treatment of the disease, with disparate results according to drug and regimen used. For this reason, we wanted to analyze differences in early mortality derived from the use of different regimens of dexamethasone and methylprednisolone in SARS-CoV-2 infection in critically ill patients requiring admission to an ICU | ||
| 520 | |a METHOD: Observational, analytical and retrospective study, in an intensive care unit of a third-level university hospital, (March 2020 and June 2021). Adult patients (>18 years old) who were admitted consecutively for proven SARS-CoV-2 infection were included. The association with mortality in ICU at 28 days, different corticosteroid regimens used, was analyzed using a Cox proportional risk regression model | ||
| 520 | |a RESULTS: Data from a cohort of 539 patients were studied. Patient age (RR: 1.06; 95% CI: 1.02-1.10; P=<0.01) showed a significant association with 28-day mortality in the ICU. In the comparison of the different corticosteroid regimens analyzed, taking as a reference those patients who did not receive corticosteroid treatment, the dose of dexamethasone of 6mg/day showed a clear trend towards statistical significance as a protector of mortality at 28 days in the ICU (RR: 0.40, 95% CI: 0.15-1.02, p=0.05). The dose of dexamethasone of 6mg/day and low doses of methylprednisolone show a similar association with survival at 28 days (OR: 1.19; 95% CI: 0.63-2.26) | ||
| 520 | |a CONCLUSIONS: The use of corticosteroids has been associated with better mortality outcomes in severe cases of SARS-CoV-2 infection. However, the therapeutic benefits of corticosteroids are not limited to dexamethasone alone | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 28-day mortality | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Covid | |
| 650 | 4 | |a Dexametasona | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Methylprednisolone | |
| 650 | 4 | |a Metilprednisolona | |
| 650 | 4 | |a Mortalidad a corto plazo | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Fernandez, A |e verfasserin |4 aut | |
| 700 | 1 | |a Cuenca-Fito, E |e verfasserin |4 aut | |
| 700 | 1 | |a Peñasco, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Ceña, J |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez Borregán, J C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de anestesiologia y reanimacion |d 2012 |g (2024) vom: 21. Feb. |w (DE-627)NLM222859482 |x 2341-1929 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.redare.2024.02.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 02 | ||